DOI:
10.1055/s-00034925
Hämostaseologie
LinksClose Window
References
Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ. CANTOS Trial Group.
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.
Lancet 2018;
391 (10118): 319-328
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.